Abstract
Objective: The purpose of this study was to determine the ex vivo human placental transfer of rifampin and rifabutin.
Methods: Seven placentas from uncomplicated term vaginal or cesarean deliveries were studied utilizing the ex vivo single cotyledon perfusion system. Antipyrine was used for the reference compound in the determination of the clearance indices of rifampin and rifabutin.
Results: The clearance indices of rifampin at maternal concentrations of 1.0 and 10.0 μg/ml were 0.12 ± 0.05 and 0.12 ± 0.11, respectively. The clearance indices of rifabutin at maternal concentrations of 1.0 and 10.0 μg/ml were 0.44 ± 0.11 and 0.37 ± 0.15, respectively.
Conclusions: Because of its greater lipophilicity, rifabutin was found to have a greater clearance than rifampin. However, because of rifabutin's trend toward greater deposition in tissue, there was proportionately less accumulation of rifabutin in the fetal circulation when compared to rifampin.
Full Text
The Full Text of this article is available as a PDF (293.1 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- American Thoracic Society. Medical Section of the American Lung Association: Treatment of tuberculosis and tuberculosis infection in adults and children. Am Rev Respir Dis. 1986 Aug;134(2):355–363. doi: 10.1164/arrd.1986.134.2.355. [DOI] [PubMed] [Google Scholar]
- Brogden R. N., Fitton A. Rifabutin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1994 Jun;47(6):983–1009. doi: 10.2165/00003495-199447060-00008. [DOI] [PubMed] [Google Scholar]
- Challier J. C. Criteria for evaluating perfusion experiments and presentation of results. Contrib Gynecol Obstet. 1985;13:32–39. [PubMed] [Google Scholar]
- Hartmann G., Honikel K. O., Knüsel F., Nüesch J. The specific inhibition of the DNA-directed RNA synthesis by rifamycin. Biochim Biophys Acta. 1967;145(3):843–844. doi: 10.1016/0005-2787(67)90147-5. [DOI] [PubMed] [Google Scholar]
- Kenny M. T., Strates B. Metabolism and pharmacokinetics of the antibiotic rifampin. Drug Metab Rev. 1981;12(1):159–218. doi: 10.3109/03602538109011084. [DOI] [PubMed] [Google Scholar]
- Moore D. J., Perrino P. J., Klerer C. P., Robertson P. High-performance liquid chromatographic assay for two rifamycin-derived hypocholesterolemic agents in liver and biological fluids. J Chromatogr. 1993 Feb 26;612(2):310–314. doi: 10.1016/0378-4347(93)80178-7. [DOI] [PubMed] [Google Scholar]
- Nightingale S. D., Cameron D. W., Gordin F. M., Sullam P. M., Cohn D. L., Chaisson R. E., Eron L. J., Sparti P. D., Bihari B., Kaufman D. L. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med. 1993 Sep 16;329(12):828–833. doi: 10.1056/NEJM199309163291202. [DOI] [PubMed] [Google Scholar]
- Rocker I. Rifampicin in early pregnancy. Lancet. 1977 Jul 2;2(8027):48–48. doi: 10.1016/s0140-6736(77)90056-3. [DOI] [PubMed] [Google Scholar]
- Snider D. E., Jr, Layde P. M., Johnson M. W., Lyle M. A. Treatment of tuberculosis during pregnancy. Am Rev Respir Dis. 1980 Jul;122(1):65–79. doi: 10.1164/arrd.1980.122.1.65. [DOI] [PubMed] [Google Scholar]
- Sullam P. M., Gordin F. M., Wynne B. A. Efficacy of rifabutin in the treatment of disseminated infection due to Mycobacterium avium complex. The Rifabutin Treatment Group. Clin Infect Dis. 1994 Jul;19(1):84–86. doi: 10.1093/clinids/19.1.84. [DOI] [PubMed] [Google Scholar]
- Umezawa H., Mizuno S., Yamazaki H., Nitta K. Inhibition of DNA-dependent RNA synthesis by rifamycins. J Antibiot (Tokyo) 1968 Mar;21(3):234–236. doi: 10.7164/antibiotics.21.234. [DOI] [PubMed] [Google Scholar]